Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H18O11 |
| Molecular Weight | 422.3396 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)C2=C(O)C3=C(OC4=C(C=C(O)C(O)=C4)C3=O)C=C2O
InChI
InChIKey=AEDDIBAIWPIIBD-ZJKJAXBQSA-N
InChI=1S/C19H18O11/c20-4-11-15(25)17(27)18(28)19(30-11)12-8(23)3-10-13(16(12)26)14(24)5-1-6(21)7(22)2-9(5)29-10/h1-3,11,15,17-23,25-28H,4H2/t11-,15-,17+,18-,19+/m1/s1
| Molecular Formula | C19H18O11 |
| Molecular Weight | 422.3396 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Mangiferin, a bioactive compound derived primarily from Anacardiaceae and Gentianaceae families and found in mangoes and honeybush tea, has been extensively studied for its therapeutic properties. Mangiferin has shown promising chemotherapeutic and chemopreventative potential. In traditional medicine, different cultures have cultivated and processed mangiferin rich plants for the treatment of a range of illnesses including cardiovascular disease, diabetes, infection and cancer. Mangiferin is primarily implicated in down-regulating inflammation, causing cell cycle arrest, reducing proliferation/metastasis, promoting apoptosis in malignant cells and protecting against oxidative stress and DNA damage. Mangiferin also enhances the capacity of the monocyte-macrophage system and possesses antibacterial activity against gram-positive and gram-negative bacteria.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map04064 |
|||
Target ID: CHEMBL2622 |
3.2 µM [IC50] | ||
Target ID: CHEMBL4357 |
358.54 µM [IC50] | ||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
19.94 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26434292/ |
0.2 g single, oral dose: 0.2 g route of administration: Oral experiment type: SINGLE co-administered: |
MANGIFERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
38.64 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26434292/ |
0.9 g single, oral dose: 0.9 g route of administration: Oral experiment type: SINGLE co-administered: |
MANGIFERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
34.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26434292/ |
0.3 g single, oral dose: 0.3 g route of administration: Oral experiment type: SINGLE co-administered: |
MANGIFERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
167.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26434292/ |
0.2 g single, oral dose: 0.2 g route of administration: Oral experiment type: SINGLE co-administered: |
MANGIFERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
415.14 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26434292/ |
0.9 g single, oral dose: 0.9 g route of administration: Oral experiment type: SINGLE co-administered: |
MANGIFERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
269.35 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26434292/ |
0.3 g single, oral dose: 0.3 g route of administration: Oral experiment type: SINGLE co-administered: |
MANGIFERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.47 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26434292/ |
0.2 g single, oral dose: 0.2 g route of administration: Oral experiment type: SINGLE co-administered: |
MANGIFERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.85 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26434292/ |
0.9 g single, oral dose: 0.9 g route of administration: Oral experiment type: SINGLE co-administered: |
MANGIFERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
8.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26434292/ |
0.3 g single, oral dose: 0.3 g route of administration: Oral experiment type: SINGLE co-administered: |
MANGIFERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| likely [Inhibition 100 uM] | ||||
| likely [Inhibition 100 uM] | ||||
| moderate [Inhibition 100 uM] | ||||
| no [Inhibition 100 uM] | ||||
| no [Inhibition 100 uM] | ||||
| no [Inhibition 100 uM] | ||||
| no [Inhibition 100 uM] | ||||
| no [Inhibition 100 uM] | ||||
| no [Inhibition 100 uM] | ||||
| no [Inhibition 100 uM] | ||||
| no | ||||
| no | ||||
| weak [Inhibition 100 uM] | ||||
| yes [IC50 12.3 uM] | ||||
| yes [IC50 4.4 uM] | ||||
| yes [IC50 8.2 uM] | ||||
| yes [Inhibition 100 uM] | ||||
| yes [Inhibition 100 uM] | ||||
| yes [Inhibition 100 uM] | ||||
| yes [Inhibition 100 uM] | ||||
| yes [Inhibition 100 uM] | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Mangiferin treatment inhibits hepatic expression of acyl-coenzyme A:diacylglycerol acyltransferase-2 in fructose-fed spontaneously hypertensive rats: a link to amelioration of fatty liver. | 2014-10-15 |
|
| [Relationship between endothelial damage and p120-catenin in paraquat intoxication and the protective effect of mangiferin]. | 2014-06 |
|
| Up-regulation of glyoxalase 1 by mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. | 2013-12-05 |
|
| Mangiferin attenuates MPTP induced dopaminergic neurodegeneration and improves motor impairment, redox balance and Bcl-2/Bax expression in experimental Parkinson's disease mice. | 2013-11-25 |
|
| Mangiferin exerts antitumor activity in breast cancer cells by regulating matrix metalloproteinases, epithelial to mesenchymal transition, and β-catenin signaling pathway. | 2013-10-01 |
|
| Peripheral antinociceptive action of mangiferin in mouse models of experimental pain: role of endogenous opioids, K(ATP)-channels and adenosine. | 2013-09 |
|
| Mangifera indica L. extract and mangiferin modulate cytochrome P450 and UDP-glucuronosyltransferase enzymes in primary cultures of human hepatocytes. | 2013-05 |
|
| Protective nature of mangiferin on oxidative stress and antioxidant status in tissues of streptozotocin-induced diabetic rats. | 2013 |
|
| Mangiferin, a natural xanthone, protects murine liver in Pb(II) induced hepatic damage and cell death via MAP kinase, NF-κB and mitochondria dependent pathways. | 2013 |
|
| Selective inhibition of MMP-9 gene expression by mangiferin in PMA-stimulated human astroglioma cells: involvement of PI3K/Akt and MAPK signaling pathways. | 2012-07 |
|
| Neuropharmacological effect of Mangiferin on brain cholinesterase and brain biogenic amines in the management of Alzheimer's disease. | 2012-05-15 |
|
| Mangiferin exerts hepatoprotective activity against D-galactosamine induced acute toxicity and oxidative/nitrosative stress via Nrf2-NFκB pathways. | 2012-04-01 |
|
| D(+) galactosamine induced oxidative and nitrosative stress-mediated renal damage in rats via NF-κB and inducible nitric oxide synthase (iNOS) pathways is ameliorated by a polyphenol xanthone, mangiferin. | 2012-02 |
|
| Mangiferin, a dietary xanthone protects against mercury-induced toxicity in HepG2 cells. | 2012-02 |
|
| Norathyriol suppresses skin cancers induced by solar ultraviolet radiation by targeting ERK kinases. | 2012-01-01 |
|
| Mangiferin ameliorates 6-hydroxydopamine-induced cytotoxicity and oxidative stress in ketamine model of schizophrenia. | 2012 |
|
| Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats. | 2012 |
|
| Cardioprotective effect of mangiferin on left ventricular remodeling in rats. | 2012 |
|
| Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK. | 2012 |
|
| Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters. | 2011-12 |
|
| Polysulfated xanthones: multipathway development of a new generation of dual anticoagulant/antiplatelet agents. | 2011-08-11 |
|
| Gallic acid indanone and mangiferin xanthone are strong determinants of immunosuppressive anti-tumour effects of Mangifera indica L. bark in MDA-MB231 breast cancer cells. | 2011-06-01 |
|
| Mangiferin, an anti-HIV-1 agent targeting protease and effective against resistant strains. | 2011-05-24 |
|
| [Effects of mangiferin on cytokines in rats with chronic bronchitis and expression of macrophage COX-2 in mice]. | 2011-05 |
|
| Mangiferin: a possible strategy for periodontal disease to therapy. | 2011-04 |
|
| Mangiferin induces apoptosis by suppressing Bcl-xL and XIAP expressions and nuclear entry of NF-κB in HL-60 cells. | 2011-03 |
|
| Mangiferin attenuates osteoclastogenesis, bone resorption, and RANKL-induced activation of NF-κB and ERK. | 2011-01 |
|
| The Ayurvedic Medicine Salacia oblonga Attenuates Diabetic Renal Fibrosis in Rats: Suppression of Angiotensin II/AT1 Signaling. | 2011 |
|
| A Mangifera indica L. extract could be used to treat neuropathic pain and implication of mangiferin. | 2010-12-09 |
|
| [Mangiferin promotes uric acid excretion and kidney function improvement and modulates related renal transporters in hyperuricemic mice]. | 2010-10 |
|
| Establishment of a novel model for studying the effects of extracts of Chinese herb medicine on human type II 5alpha-reductase in vitro. | 2010-09 |
|
| In vitro modulation of ABCB1/P-glycoprotein expression by polyphenols from Mangifera indica. | 2010-08-05 |
|
| Mangiferin, a naturally occurring glucoxilxanthone improves long-term object recognition memory in rats. | 2010-06-10 |
|
| Mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. | 2010-06 |
|
| Study on interaction of mangiferin to insulin and glucagon in ternary system. | 2010-05 |
|
| [Effects of mangiferin on cell cycle status and CDC2/Cyclin B1 expression of HL-60 cells]. | 2010-01 |
|
| Agarwood induced laxative effects via acetylcholine receptors on loperamide-induced constipation in mice. | 2010 |
|
| Salacia oblonga extract increases glucose transporter 4-mediated glucose uptake in L6 rat myotubes: role of mangiferin. | 2009-10 |
|
| Spectroscopic investigation of interaction between mangiferin and bovine serum albumin. | 2009-09-01 |
|
| Mechanism of protective action of mangiferin on suppression of inflammatory response and lysosomal instability in rat model of myocardial infarction. | 2009-06 |
|
| Effect of mangiferin on the development of periodontal disease: involvement of lipoxin A4, anti-chemotaxic action in leukocyte rolling. | 2009-05-15 |
|
| Characterization of the mangiferin-human serum albumin complex by spectroscopic and molecular modeling approaches. | 2009-04-05 |
|
| Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols. | 2009-04 |
|
| Mangiferin ameliorates scopolamine-induced learning deficits in mice. | 2009-02 |
|
| Mechanisms of blood glucose-lowering effect of aqueous extract from stems of Kothala himbutu (Salacia reticulata) in the mouse. | 2009-01-21 |
|
| Cytoprotective effect of mangiferin on benzo(a)pyrene-induced lung carcinogenesis in swiss albino mice. | 2008-08 |
|
| New antidiabetic compounds, mangiferin and its glucoside. | 1998-12 |
|
| The effect of Kampo formulae on bone resorption in vitro and in vivo. I. Active constituents of Tsu-kan-gan. | 1998-12 |
|
| Antitumor, immunomodulatory and anti-HIV effect of mangiferin, a naturally occurring glucosylxanthone. | 1996-11-01 |
|
| Scavenging effect of Chinonin on NO and oxygen free radicals and its protective effect on the myocardium from the injury of ischemia-reperfusion. | 1996-03-01 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Humans: Participants were randomly allocated to groups, either receiving mangiferin (150 mg/day, p.o) or identical placebo for 12 weeks. https://www.ncbi.nlm.nih.gov/pubmed/25989216
Mouse tumor xenograft model: Mangiferin (10, 50 and 100 mg/kg) was intraperitoneally injected into the
mice, and the therapy lasted for 2 weeks
Route of Administration:
Intraperitoneal
Mangiferin (30–300 uM), isolated from A. asphodeloides, specifi-
cally inhibited MMP-9 gene expression in PMA-stimulated
human astroglioma U87MG, U373MG, and CRT-MG cells. Mangiferin (80 uM) could inhibit the proliferation of HL-60, block
the cell cycle progression in G2/M phase, and significantly
increased the expressions of CDC2 mRNA and Cyclin B1 mRNA
of HL-60 cells.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:47:27 GMT 2025
by
admin
on
Mon Mar 31 18:47:27 GMT 2025
|
| Record UNII |
1M84LD0UMD
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
4454 (Number of products:4)
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1M84LD0UMD
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | |||
|
100000182948
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | |||
|
C013592
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | |||
|
6682
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | |||
|
248870
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | |||
|
DTXSID60197263
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | |||
|
5281647
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | |||
|
1375156
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | |||
|
4773-96-0
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | |||
|
1M84LD0UMD
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | |||
|
MANGIFERIN
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | |||
|
1362895
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB197209
Created by
admin on Mon Mar 31 18:47:27 GMT 2025 , Edited by admin on Mon Mar 31 18:47:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
